Potential of hybrid 18F-fluorocholine PET/MRI for prostate cancer imaging

PurposeTo report the first results of hybrid 18F-fluorocholine PET/MRI imaging for the detection of prostate cancer.MethodsThis analysis included 26 consecutive patients scheduled for prostate PET/MRI before radical prostatectomy. The examinations were performed on a hybrid whole-body PET/MRI scanner. The MR acquisitions which included T2-weighted, diffusion-weighted and dynamic contrast-enhanced sequences were followed during the same session by whole-body PET scans. Parametric maps were constructed to measure normalized T2-weighted intensity (nT2), apparent diffusion coefficient (ADC), volume transfer constant (Ktrans), extravascular extracellular volume fraction (ve) and standardized uptake values (SUV). With pathology as the gold standard, ROC curves were calculated using logistic regression for each parameter and for the best combination with and without PET to obtain a MR model versus a PETMR model.ResultsOf the 26 patients initially selected, 3 were excluded due to absence of an endorectal coil (2 patients) or prosthesis artefacts (1 patient). In the whole prostate, the area under the curve (AUC) for SUVmax, ADC, nT2, Ktrans and ve were 0.762, 0.756, 0.685, 0.611 and 0.529 with a best threshold at 3.044 for SUVmax and 1.075 × 10−3 mm2/s for ADC. The anatomical distinction between the transition zone and the peripheral zone showed the potential of the adjunctive use of PET. In the peripheral zone, the AUC of 0.893 for the PETMR model was significantly greater (p = 0.0402) than the AUC of 0.84 for the MR model only. In the whole prostate, no relevant correlation was observed between ADC and SUVmax. The SUVmax was not affected by the Gleason score.ConclusionThe performance of a hybrid whole-body 18F-fluorocholine PET/MRI scan in the same session combined with a prostatic MR examination did not interfere with the diagnostic accuracy of the MR sequences. The registration of the PET data and the T2 anatomical MR sequence data allowed precise localization of hypermetabolic foci in the prostate. While in the transition zone the adenomatous hyperplasia interfered with cancer detection by PET, the quantitative analysis tool performed well for cancer detection in the peripheral zone.

[1]  Volker Schmid,et al.  Quantitative Analysis of Dynamic Contrast-Enhanced and Diffusion-Weighted Magnetic Resonance Imaging for Oncology in R , 2011 .

[2]  S. Ziegler,et al.  Tumour volume delineation in prostate cancer assessed by [11C]choline PET/CT: validation with surgical specimens , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  J. Machan,et al.  Diffusion-weighted MRI of peripheral zone prostate cancer: comparison of tumor apparent diffusion coefficient with Gleason score and percentage of tumor on core biopsy. , 2010, AJR. American journal of roentgenology.

[4]  R. Miralbell,et al.  Evaluation of [18F]-choline PET/CT for staging and restaging of prostate cancer , 2008, European Journal of Nuclear Medicine and Molecular Imaging.

[5]  S. Y. Park,et al.  Diffusion-Weighted Imaging of a Prostate Cancer Xenograft Model Seen on a 7 Tesla Animal MR Scanner: Comparison of ADC Values and Pathologic Findings , 2011, Korean journal of radiology.

[6]  H. Huisman,et al.  Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. , 2006, Radiology.

[7]  Mario Marengo,et al.  Detection and localization of prostate cancer: correlation of (11)C-choline PET/CT with histopathologic step-section analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  M. Schouten,et al.  Predictive value of MRI in the localization, staging, volume estimation, assessment of aggressiveness, and guidance of radiotherapy and biopsies in prostate cancer , 2012, Journal of magnetic resonance imaging : JMRI.

[9]  Daniel U. Campos-Delgado,et al.  Non-rigid multimodal image registration based on local variability measures and optical flow , 2012, 2012 Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

[10]  S. Verma,et al.  Assessment of aggressiveness of prostate cancer: correlation of apparent diffusion coefficient with histologic grade after radical prostatectomy. , 2011, AJR. American journal of roentgenology.

[11]  J. Pruim,et al.  In vivo uptake of [11C]choline does not correlate with cell proliferation in human prostate cancer , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  Karsten Tabelow,et al.  Image analysis and statistical inference in neuroimaging with R , 2011, NeuroImage.

[13]  F. Fazio,et al.  11C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. , 2008, European urology.

[14]  Cher Heng Tan,et al.  Diffusion weighted imaging in prostate cancer , 2011, European Radiology.

[15]  R. Günther,et al.  Automatic, three-segment, MR-based attenuation correction for whole-body PET/MR data , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  R. Shah,et al.  Introducing Parametric Fusion PET/MRI of Primary Prostate Cancer , 2012, The Journal of Nuclear Medicine.

[17]  F. Mottaghy,et al.  Is there an additional value of ¹¹C-choline PET-CT to T2-weighted MRI images in the localization of intraprostatic tumor nodules? , 2012, International journal of radiation oncology, biology, physics.

[18]  A. Evans,et al.  Prostate cancer detection with multi‐parametric MRI: Logistic regression analysis of quantitative T2, diffusion‐weighted imaging, and dynamic contrast‐enhanced MRI , 2009, Journal of magnetic resonance imaging : JMRI.

[19]  A. Padhani Integrating multiparametric prostate MRI into clinical practice , 2011, Cancer imaging : the official publication of the International Cancer Imaging Society.

[20]  A. Ahmadian,et al.  MRI-guided attenuation correction in whole-body PET/MR: assessment of the effect of bone attenuation , 2013, Annals of Nuclear Medicine.

[21]  H. Zaidi,et al.  Three-phase 18F-fluorocholine PET/CT in the evaluation of prostate cancer recurrence , 2008, Nuklearmedizin.

[22]  M. Schwaiger,et al.  The detection rate of [11C]Choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  Namkug Kim,et al.  Apparent diffusion coefficient: Prostate cancer versus noncancerous tissue according to anatomical region , 2008, Journal of magnetic resonance imaging : JMRI.

[24]  N. Rofsky,et al.  MR imaging relaxation times of abdominal and pelvic tissues measured in vivo at 3.0 T: preliminary results. , 2004, Radiology.

[25]  E. Rostrup,et al.  Measurement of the arterial concentration of Gd‐DTPA using MRI: A step toward quantitative perfusion imaging , 1996, Magnetic resonance in medicine.

[26]  T. Shiga,et al.  Accumulation of [11C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer , 2002, European Journal of Nuclear Medicine and Molecular Imaging.

[27]  P. Tofts,et al.  Measurement of the blood‐brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts , 1991, Magnetic resonance in medicine.

[28]  Eveliina Arponen,et al.  Improved detection of localized prostate cancer using co-registered MRI and 11C-acetate PET/CT. , 2012, European journal of radiology.

[29]  C. Nanni,et al.  Influence of Trigger PSA and PSA Kinetics on 11C-Choline PET/CT Detection Rate in Patients with Biochemical Relapse After Radical Prostatectomy , 2009, Journal of Nuclear Medicine.

[30]  J. Mintorovitch,et al.  Comparison of Magnetic Properties of MRI Contrast Media Solutions at Different Magnetic Field Strengths , 2005, Investigative radiology.

[31]  J. Ferlay,et al.  Estimates of the cancer incidence and mortality in Europe in 2006. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  J. Talbot,et al.  18F-choline PET/CT for initial staging of advanced prostate cancer. , 2006, AJR. American journal of roentgenology.

[33]  P. Carroll,et al.  Prostate cancer: effect of postbiopsy hemorrhage on interpretation of MR images. , 1995, Radiology.

[34]  Thomas Hambrock,et al.  Initial Experience With Identifying High-Grade Prostate Cancer Using Diffusion-Weighted MR Imaging (DWI) in Patients With a Gleason Score ⩽3 + 3 = 6 Upon Schematic TRUS-Guided Biopsy: A Radical Prostatectomy Correlated Series , 2012, Investigative radiology.

[35]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[36]  G. V. von Schulthess,et al.  Fluorocholine PET/CT in patients with prostate cancer: initial experience. , 2005, Radiology.

[37]  Takeshi Yoshikawa,et al.  Clinical utility of apparent diffusion coefficient values obtained using high b‐value when diagnosing prostate cancer using 3 tesla MRI: Comparison between ultra‐high b‐value (2000 s/mm2) and standard high b‐value (1000 s/mm2) , 2012, Journal of magnetic resonance imaging : JMRI.

[38]  F Fazio,et al.  Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. , 2003, The Journal of urology.

[39]  H. Zaidi,et al.  Design and performance evaluation of a whole-body Ingenuity TF PET–MRI system , 2011, Physics in medicine and biology.

[40]  A. Oto,et al.  Diffusion-weighted and dynamic contrast-enhanced MRI of prostate cancer: correlation of quantitative MR parameters with Gleason score and tumor angiogenesis. , 2011, AJR. American journal of roentgenology.

[41]  Y. Liu,et al.  Dynamic contrast-enhanced MRI of benign prostatic hyperplasia and prostatic carcinoma: correlation with angiogenesis. , 2008, Clinical radiology.

[42]  Xavier Robin,et al.  pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.

[43]  P. Waldenberger,et al.  18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients. , 2010, Radiology.

[44]  Gary P Liney,et al.  Correlation of ADC and T2 Measurements With Cell Density in Prostate Cancer at 3.0 Tesla , 2009, Investigative radiology.

[45]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[46]  Takeo Ishigaki,et al.  Prostate cancer detection with 3-T MRI: comparison of diffusion-weighted and T2-weighted imaging. , 2007, European journal of radiology.

[47]  V. Khoo,et al.  Intensity Modulated Radiation Therapy Dose Painting for Localized Prostate Cancer Using 11 C-choline Positron , 2012 .